Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

Opens in a new tab or window A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to have inadequate bowel preparation for ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy, gestational diabetes, have a preterm birth or cesarean ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Even as millions of older adults clamor for drugs such as Ozempic and Wegovy, monthly use of the medications known as GLP-1 receptor agonists soared nearly 600% between 2020 and 2023 in people ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...